233 related articles for article (PubMed ID: 12010224)
21. [Recurrent Kidney Stones in a patient with Malabsorption Syndrome].
Bargagli M; Fulignati P; D'Alonzo S; Naticchia A; Galli D; Ferraro PM
G Ital Nefrol; 2018 Jul; 35(4):. PubMed ID: 30035444
[TBL] [Abstract][Full Text] [Related]
22. Urinary excretion of citrate, glycosaminoglycans, magnesium and zinc in relation to age and sex in normal subjects and in patients who form calcium stones.
Trinchieri A; Mandressi A; Luongo P; Rovera F; Longo G
Scand J Urol Nephrol; 1992; 26(4):379-86. PubMed ID: 1292077
[TBL] [Abstract][Full Text] [Related]
23. Lipid peroxidation and its correlations with urinary levels of oxalate, citric acid, and osteopontin in patients with renal calcium oxalate stones.
Huang HS; Ma MC; Chen CF; Chen J
Urology; 2003 Dec; 62(6):1123-8. PubMed ID: 14665375
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of factors involved in calcium stone formation.
Abraham PA; Smith CL
Miner Electrolyte Metab; 1987; 13(3):201-8. PubMed ID: 3627051
[TBL] [Abstract][Full Text] [Related]
25. Lithogenic risk factors for renal stones in patients with Crohn's disease.
Buño Soto A; Torres Jiménez R; Olveira A; Fernández-Blanco Herraiz I; Montero García A; Mateos Antón F
Arch Esp Urol; 2001 Apr; 54(3):282-92. PubMed ID: 11432047
[TBL] [Abstract][Full Text] [Related]
26. Absorptive hyperoxaluria leads to an increased risk for urolithiasis or nephrocalcinosis in cystic fibrosis.
Hoppe B; von Unruh GE; Blank G; Rietschel E; Sidhu H; Laube N; Hesse A
Am J Kidney Dis; 2005 Sep; 46(3):440-5. PubMed ID: 16129205
[TBL] [Abstract][Full Text] [Related]
27. Changes in urinary parameters after oral administration of potassium-sodium citrate and magnesium oxide to prevent urolithiasis.
Kato Y; Yamaguchi S; Yachiku S; Nakazono S; Hori J; Wada N; Hou K
Urology; 2004 Jan; 63(1):7-11; discussion 11-2. PubMed ID: 14751336
[TBL] [Abstract][Full Text] [Related]
28. Different dietary calcium intake and relative supersaturation of calcium oxalate in the urine of patients forming renal stones.
Messa P; Marangella M; Paganin L; Codardini M; Cruciatti A; Turrin D; Filiberto Z; Mioni G
Clin Sci (Lond); 1997 Sep; 93(3):257-63. PubMed ID: 9337641
[TBL] [Abstract][Full Text] [Related]
29. Oxalate status in stone-formers. Two distinct hyperoxaluric entities.
Hatch M
Urol Res; 1993 Jan; 21(1):55-9. PubMed ID: 8456539
[TBL] [Abstract][Full Text] [Related]
30. Use of a probiotic to decrease enteric hyperoxaluria.
Lieske JC; Goldfarb DS; De Simone C; Regnier C
Kidney Int; 2005 Sep; 68(3):1244-9. PubMed ID: 16105057
[TBL] [Abstract][Full Text] [Related]
31. Contributory metabolic factors in the development of nephrolithiasis in patients with medullary sponge kidney.
Yagisawa T; Kobayashi C; Hayashi T; Yoshida A; Toma H
Am J Kidney Dis; 2001 Jun; 37(6):1140-3. PubMed ID: 11382681
[TBL] [Abstract][Full Text] [Related]
32. [Effect of verapamil on urinary calcium and oxalate excretion in renal stone formers].
Iguchi M; Ikegami M; Kiwamoto H; Umekawa T; Ishikawa Y; Kohri K; Kurita T
Hinyokika Kiyo; 1993 May; 39(5):425-31. PubMed ID: 8322624
[TBL] [Abstract][Full Text] [Related]
33. Age, Body Mass Index, and Gender Predict 24-Hour Urine Parameters in Recurrent Idiopathic Calcium Oxalate Stone Formers.
Otto BJ; Bozorgmehri S; Kuo J; Canales M; Bird VG; Canales B
J Endourol; 2017 Dec; 31(12):1335-1341. PubMed ID: 29084490
[TBL] [Abstract][Full Text] [Related]
34. Calcium stone disease: a multiform reality.
Trinchieri A; Castelnuovo C; Lizzano R; Zanetti G
Urol Res; 2005 Jun; 33(3):194-8. PubMed ID: 15714335
[TBL] [Abstract][Full Text] [Related]
35. Reduction of renal stone risk by potassium-magnesium citrate during 5 weeks of bed rest.
Zerwekh JE; Odvina CV; Wuermser LA; Pak CY
J Urol; 2007 Jun; 177(6):2179-84. PubMed ID: 17509313
[TBL] [Abstract][Full Text] [Related]
36. Hypocitraturia in patients with gastrointestinal malabsorption.
Rudman D; Dedonis JL; Fountain MT; Chandler JB; Gerron GG; Fleming GA; Kutner MH
N Engl J Med; 1980 Sep; 303(12):657-61. PubMed ID: 7402252
[TBL] [Abstract][Full Text] [Related]
37. [Citrate and kidney stones].
Osther PJ
Ugeskr Laeger; 1993 Nov; 155(47):3835-9. PubMed ID: 8256384
[TBL] [Abstract][Full Text] [Related]
38. Body size and 24-hour urine composition.
Taylor EN; Curhan GC
Am J Kidney Dis; 2006 Dec; 48(6):905-15. PubMed ID: 17162145
[TBL] [Abstract][Full Text] [Related]
39. Renal tubular cell damage and oxidative stress in renal stone patients and the effect of potassium citrate treatment.
Tungsanga K; Sriboonlue P; Futrakul P; Yachantha C; Tosukhowong P
Urol Res; 2005 Feb; 33(1):65-9. PubMed ID: 15565439
[TBL] [Abstract][Full Text] [Related]
40. Comparison of patients with idiopathic calcium phosphate and calcium oxalate stones.
Gault MH; Chafe LL; Morgan JM; Parfrey PS; Harnett JD; Walsh EA; Prabhakaran VM; Dow D; Colpitts A
Medicine (Baltimore); 1991 Nov; 70(6):345-59. PubMed ID: 1956278
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
